Cited by 352SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 47 of the 52 references it cites were found in a registry or an index.

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Open access

Atyeo, Caroline, Fischinger, Stephanie, Zohar, Tomer, Slein, Matthew D., Burke, John, Loos, Carolin, McCulloch, Denise J., Newman, Kira L., Wolf, Caitlin, Yu, Jingyou, Shuey, Kiel, Feldman, Jared, Hauser, Blake Marie, Caradonna, Tim, Schmidt, Aaron G., Suscovich, Todd J., Linde, Caitlyn, Cai, Yongfei, Barouch, Dan, Ryan, Edward T., Charles, Richelle C., Lauffenburger, Douglas, Chu, Helen, Alter, Galit·2020·Immunity

DOI 10.1016/j.immuni.2020.07.020PMC PMC7392190

Open this paper in CoChat — free account Open PDF

Abstract

As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.07.020

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Scikit-learn: Machine Learning in Python
Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Müller, A., Nothman, J., Louppe, G., et al. (2012) · arXiv · doi:10.48550/arxiv.1201.0490 · Cited by 71,016
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
An introduction to variable and feature selection
GuyonIsabelle, & ElisseeffAndré (2003) · Journal of Machine Learning Research · doi:10.5555/944919.944968 · Cited by 8,354
An Introduction to Variable and Feature Selection.
Guyon, I., & Elisseeff, A. (2003) · Cited by 6,576
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S. N. J., Wurfel, M. M., Evans, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004500 · Cited by 2,588

Flagged first, then by citations

Show all 52 references

5 of the 52 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Wang, 2020, Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients, Clin. Infect. Dis.

Sorted by citations

Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
Tan, A. T., Linster, M., Tan, C. W., Le Bert, N., Chia, W. N., Kunasegaran, K., Zhuang, Y., Tham, C. Y. L., Chia, A., Smith, G. J. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108728 · Cited by 740
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer, K., Barrett, J. R., Belij‐Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R., Flaxman, A. L., Wright, D., Bellamy, D. G., Bittaye, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-01194-5 · Cited by 587
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19
Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S., Kusnadi, A., Simon, H. A., Eschweiler, S., Grifoni, A., Pelosi, E., Weiskopf, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.001 · Cited by 581
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1555 · Cited by 475
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
Röltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe0240 · Cited by 452
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.029 · Cited by 345
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
Ripperger, T. J., Uhrlaub, J. L., Watanabe, M., Wong, R., Castaneda, Y., Pizzato, H. A., Thompson, M. R., Bradshaw, C. M., Weinkauf, C. C., Bime, C., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.004 · Cited by 338
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
Le Bert, N., Clapham, H. E., Tan, A. T., Chia, W. N., Tham, C. Y. L., Lim, J. M., Kunasegaran, K., Tan, L. W. L., Dutertre, C.-A., Shankar, N., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202617 · Cited by 330
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett, J. R., Belij-Rammerstorfer, S., Dold, C., Ewer, K. J., Folegatti, P. M., Gilbride, C., Halkerston, R., Hill, J., Jenkin, D., Stockdale, L., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01179-4 · Cited by 315
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297
Self-citation
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
Voss, W. N., Hou, Y. J., Johnson, N. V., Delidakis, G., Kim, J. E., Javanmardi, K., Horton, A. P., Bartzoka, F., Paresi, C., Tanno, Y., et al. (2021) · Science · doi:10.1126/science.abg5268 · Cited by 255
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel, E., Reix, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103561 · Cited by 234
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas, C. G. D. O., Klein, J., Sundaram, M. E., Liu, F., Wong, P., Silva, J. D. S., Mao, T., Oh, J. E., Mohanty, S., Huang, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01355-0 · Cited by 289
COVID-19 Antibody Tests and Their Limitations
Liu, G., & Rusling, J. F. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02621 · Cited by 226
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 225
Compromised SARS-CoV-2-specific placental antibody transfer
Atyeo, C. G., Pullen, K. M., Bordt, E. A., Fischinger, S., Burke, J. S., Michell, A. R., Slein, M. D., Loos, C., Shook, L. L., Boatin, A. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.027 · Cited by 207
Self-citation
Overview of SARS-CoV-2 infection in adults living with HIV
Ambrosioni, J., Blanco, J. L., Reyes‐Urueña, J., Davies, M., Sued, O. G., Marcos, M. Á., Martínez, E., Bertagnolio, S., Alcamí, J., Miró, J. M., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00070-9 · Cited by 211
A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
de Alwis, R., Gan, E. S., Chen, S., Leong, Y. S., Tan, H. C., Zhang, S. L., Yau, C., Low, J. G. H., Kalimuddin, S., Matsuda, D., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.001 · Cited by 191
Systems serology detects functionally distinct coronavirus antibody features in children and elderly
Selva, K. J., van de Sandt, C. E., Lemke, M. M., Lee, C. Y., Shoffner, S. K., Chua, B. Y. L., Davis, S. K., Nguyen, T. H. O., Rowntree, L. C., Hensen, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22236-7 · Cited by 179
Defining the risk of SARS-CoV-2 variants on immune protection
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168
Self-citation
Humoral signatures of protective and pathological SARS-CoV-2 infection in children
Bartsch, Y. C., Wang, C., Zohar, T., Fischinger, S., Atyeo, C. G., Burke, J. S., Kang, J., Edlow, A. G., Fasano, A., Baden, L. R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01263-3 · Cited by 163
Self-citation
Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions
Bunders, M. J., & Altfeld, M. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.003 · Cited by 167
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K., Yiu, K., Chan, T., Bull, M., Ling, K. C., Dai, Z., et al. (2022) · Respirology · doi:10.1111/resp.14191 · Cited by 162
Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes
Jacobs, J. L., Bain, W., Naqvi, A., Staines, B., Castanha, P. M. S., Yang, H., Boltz, V. F., Barratt‐Boyes, S. M., Marques, E. T. A., Mitchell, S. L., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab686 · Cited by 137
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets
Dugan, H. L., Stamper, C. T., Li, L., Changrob, S., Asby, N. W., Halfmann, P. J., Zheng, N.-Y., Huang, M., Shaw, D. G., Cobb, M. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.001 · Cited by 134
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 143
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
Kapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm2311 · Cited by 136
Self-citation
Severity of COVID-19 at elevated exposure to perfluorinated alkylates
Grandjean, P., Timmermann, C. A. G., Kruse, M., Nielsen, F., Vinholt, P. J., Boding, L., Heilmann, C., & Mølbak, K. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244815 · Cited by 131
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121
Self-citation
Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
Klingler, J., Weiß, S., Itri, V., Liu, X., Oguntuyo, K. Y., Stevens, C. S., Ikegame, S., Hung, C.-T., Enyindah-Asonye, G. M., Amanat, F., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa784 · Cited by 123
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 120
mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
Kapłonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y. C., Kang, J., Burke, J. S., Shin, S. A., Dayal, D., Martin, P., Mann, C. J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.001 · Cited by 121
Self-citation
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike
Guthmiller, J. J., Stovicek, O., Wang, J., Changrob, S., Li, L., Halfmann, P., Zheng, N., Utset, H. A., Stamper, C. T., Dugan, H. L., et al. (2021) · mBio · doi:10.1128/mbio.02940-20 · Cited by 116
COVID-19 antibodies on trial
DeFrancesco, L. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0732-8 · Cited by 114
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
Dobaño, C., Santano, R., Jiménez, A., Vidal, M., Chi, J., Melero, N. R., Popovic, M., López-Aladid, R., Fernández‐Barat, L., Tortajada, M., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.02.006 · Cited by 110
A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients
Karaba, A. H., Zhu, X., Liang, T., Wang, K., Rittenhouse, A. G., Akinde, O., Eby, Y. J., Ruff, J. E., Blankson, J. N., Abedon, A. T., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16933 · Cited by 110
Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity
Yates, J. L., Ehrbar, D. J., Hunt, D., Girardin, R. C., Dupuis, A. P., Payne, A. F., Sowizral, M., Varney, S. D., Kulas, K. E., Demarest, V. L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100329 · Cited by 104
SARS-CoV-2 Antiviral Therapy
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 109
Sepsis – it is all about the platelets
Cox, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210219 · Cited by 101
The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients
Luo, H., Jia, T., Chen, J., Zeng, S., Qiu, Z., Wu, S., Li, X., Lei, Y., Wang, X., Wu, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632814 · Cited by 97
Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K. E., Wieland‐Alter, W., Connor, R. I., Wright, P. F., et al. (2021) · mBio · doi:10.1128/mbio.00765-21 · Cited by 99
Genome-Wide Asymptomatic B-Cell, CD4+ and CD8+ T-Cell Epitopes, that are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines
Prakash, S., Srivastava, R., Coulon, P.-G. A., Dhanushkodi, N. R., Chentoufi, A. A., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001438 · Cited by 91
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A., Planchais, C., Buchrieser, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100275 · Cited by 89
COVID-19: Inflammatory Profile
Wang, Y., & Perlman, S. M. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-012417 · Cited by 93
SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
Fielding, C. A., Sabberwal, P., Williamson, J. C., Greenwood, E. J. D., Crozier, T. W. M., Zelek, W. M., Seow, J., Graham, C., Huettner, I., Edgeworth, J. D., et al. (2022) · eLife · doi:10.7554/elife.74489 · Cited by 87
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
Self-citation
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
Boonyaratanakornkit, J. B., Morishima, C., Selke, S., Zamora, D., McGuffin, S. A., Shapiro, A. E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144930 · Cited by 74
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj2901 · Cited by 77
Self-citation
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · doi:10.1101/2021.01.19.427324 · Cited by 361
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 74
The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
Shiakolas, A. R., Kramer, K. J., Wrapp, D., Richardson, S. I., Schäfer, A., Wall, S. C., Wang, N., Janowska, K., Pilewski, K. A., Venkat, R., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100313 · Cited by 75
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
Francica, J. R., Flynn, B. J., Foulds, K. E., Noe, A. T., Werner, A. P., Moore, I. N., Gagné, M., Johnston, T. S., Tucker, C., Davis, R. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4547 · Cited by 89
Self-citation
Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids
Zhao, H., Wu, D., Nguyen, A., Li, Y., Adão, R. C., Valkov, E., Patterson, G. H., Piszczek, G., & Schuck, P. (2021) · iScience · doi:10.1016/j.isci.2021.102523 · Cited by 59
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Dussupt, V., Sankhala, R. S., Mendez-Rivera, L., Townsley, S., Schmidt, F., Wieczorek, L., Lal, K. G., Donofrio, G. C., Tran, U., Jackson, N. D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01068-z · Cited by 59
Antibody effector functions are associated with protection from respiratory syncytial virus
Bartsch, Y. C., Cizmeci, D., Kang, J., Zohar, T., Periasamy, S., Mehta, N., Tolboom, J. T. B. M., van der Fits, L., Sadoff, J., Comeaux, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.012 · Cited by 70
Self-citation
C1q binding to surface-bound IgG is stabilized by C1r 2 s 2 proteases
Zwarthoff, S. A., Widmer, K., Kuipers, A., Strasser, J., Ruyken, M., Aerts, P. C., de Haas, C. J. C., Ugurlar, D., den Boer, M. A., Vidarsson, G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102787118 · Cited by 62
Characterization of antibody responses to SARS‐CoV‐2 in convalescent COVID‐19 patients
Liu, C., Yu, X., Gao, C., Zhang, L., Zhai, H., Hu, Y., Liu, E., Wang, Q., Gao, Y., Wei, D., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26646 · Cited by 60
High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19
Haynes, W. A., Kamath, K., Bozekowski, J. D., Baum, E., Campbell, M., Casanovas‐Massana, A., Daugherty, P. S., Cruz, C. S. D., Dhal, A., Farhadian, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02835-2 · Cited by 60
Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality
Brunet‐Ratnasingham, E., Anand, S. P., Gantner, P., Dyachenko, A., Moquin‐Beaudry, G., Brassard, N., Beaudoin-Bussières, G., Pagliuzza, A., Gasser, R., Benlarbi, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5629 · Cited by 54
Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
Beretta, A., Cranage, M. P., & Zipeto, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.567710 · Cited by 56
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Yu, K. K. Q., Fischinger, S., Smith, M. T., Atyeo, C. G., Cizmeci, D., Wolf, C. R., Layton, E. D., Logue, J. K., Aguilar, M. S., Shuey, K. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146242 · Cited by 56
Self-citation
Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Joseph, N. T., Dude, C. M., Verkerke, H., Irby, L. S., Dunlop, A. L., Patel, R. M., Easley, K. A., Smith, A. K., Stowell, S. R., Jamieson, D. J., et al. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004440 · Cited by 57
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
Whitcombe, A. L., McGregor, R., Craigie, A., James, A., Charlewood, R., Lorenz, N., Dickson, J. M. J. J., Sheen, C. R., Koch, B., Fox‐Lewis, S., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1261 · Cited by 52
Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
Klompus, S., Leviatan, S., Vogl, T. J., Mazor, R. D., Kalka, I. N., Stoler‐Barak, L., Nathan, N., Peres, A., Moss, L., Godneva, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe9950 · Cited by 55
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
Heggestad, J. T., Kinnamon, D., Olson, L. B., Liu, J., Kelly, G., Wall, S. A., Oshabaheebwa, S., Quinn, Z., Fontes, C. M., Joh, D. Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg4901 · Cited by 52
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
Zhan, Y., Zhu, Y., Wang, S., Jia, S., Gao, Y., Lü, Y., Zhou, C.-L., Liang, R., Sun, D., Wang, X., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00777-z · Cited by 52
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 47
SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
Jarlhelt, I., Nielsen, S. K., Jahn, C. X. H., Hansen, C. B., Pérez‐Alós, L., Rosbjerg, A., Bayarri‐Olmos, R., Skjoedt, M., & Garred, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767981 · Cited by 50
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients
Pitzalis, M., Idda, M. L., Lodde, V., Loizedda, A., Lobina, M., Żołędziewska, M., Virdis, F., Delogu, G., Pirinu, F., Marini, M. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.781843 · Cited by 52
Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination
Cagigi, A., Yu, M., Österberg, B., Svensson, J., Falck‐Jones, S., Vangeti, S., Åhlberg, E., Azizmohammadi, L., Warnqvist, A., Falck‐Jones, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151463 · Cited by 48
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray
Camerini, D., Randall, A. Z., Trappl, K., Oberai, A., Hung, C., Edgar, J. M., Shandling, A. D., Huynh, V. T., Teng, A., Hermanson, G., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01416-21 · Cited by 50
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs
Stoddard, C. I., Galloway, J., Chu, H. Y., Shipley, M. M., Sung, K., Itell, H. L., Wolf, C. R., Logue, J. K., Magedson, A., Garrett, M. E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109164 · Cited by 52
Self-citation
The complexities of SARS-CoV-2 serology
Houlihan, C. F., & Beale, R. C. L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30699-x · Cited by 48
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
Bowman, K. A., Stein, D., Shin, S. A., Ferbas, K. G., Tobin, N. H., Mann, C. J., Fischinger, S., Saphire, E. O., Lauffenburger, D. A., Rimoin, A. W., et al. (2022) · mBio · doi:10.1128/mbio.01647-22 · Cited by 49
Self-citation
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., Shrestha, L. B., Keoshkerian, E., Gupta, M., Turville, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110345 · Cited by 45
Global and Regional Prevalence and Outcomes of COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis
Raya, R. P., Kamila, A., Alqahtani, J. S., Hjazi, A. M., Li, A., & Oyelade, T. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7020022 · Cited by 46
Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
Herman, J. D., Wang, C., Loos, C., Yoon, H., Rivera, J., Dieterle, M. E., Haslwanter, D., Jangra, R. K., Bortz, R. H., Bar, K. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27201-y · Cited by 39
Self-citation
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156372 · Cited by 46
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark, J. J., Hoxie, I., Adelsberg, D. C., Sapse, I. A., Andreata‐Santos, R., Yong, J. S., Amanat, F., Tcheou, J., Raskin, A. J., Singh, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114922 · Cited by 43
Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein
Supekar, N. T., Shajahan, A., Gleinich, A. S., Rouhani, D. S., Heiß, C., Chapla, D. G., Moremen, K. W., & Azadi, P. (2021) · Glycobiology · doi:10.1093/glycob/cwab044 · Cited by 43
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
Marchi, S., Viviani, S., Remarque, E. J., Ruello, A., Bombardieri, E., Bollati, V., Milani, G. P., Manenti, A., Lapini, G., Rebuffat, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253977 · Cited by 43
Application of microfluidic technologies on COVID-19 diagnosis and drug discovery
Lin, Z., Zou, Z., Pu, Z., Wu, M., & Zhang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.014 · Cited by 44
Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Lessons in antiviral immunity
Hope, J. L., & Bradley, L. M. (2021) · Science · doi:10.1126/science.abf6446 · Cited by 43
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages
Lee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 40
The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein
Chen, X., Rostad, C. A., Anderson, L. J., Sun, H.-Y., Lapp, S. A., Stephens, K., Hussaini, L., Gibson, T., Rouphael, N., & Anderson, E. J. (2021) · Virology · doi:10.1016/j.virol.2021.03.009 · Cited by 44
Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection
Pullen, K. M., Atyeo, C. G., Collier, A.-R. Y., Gray, K. J., Belfort, M. B., Lauffenburger, D. A., Edlow, A. G., & Alter, G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109959 · Cited by 41
Self-citation
COVID-19 Immunobiology: Lessons Learned, New Questions Arise
Kaklamanos, A., Belogiannis, K., Skendros, P., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Tzioufas, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719023 · Cited by 37
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Loos, C., Coccia, M., Didierlaurent, A. M., Essaghir, A., Fallon, J. K., Lauffenburger, D. A., Luedemann, C., Michell, A. R., der Most, R. G. V., Zhu, A. L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00613-1 · Cited by 38
Self-citation
Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
Keeler, S. P., & Fox, J. M. (2021) · Viruses · doi:10.3390/v13061037 · Cited by 38
50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study
Guardela, B. J., Sun, J., Zhang, T., Xu, B., Balnis, J., Huang, Y., Ma, S., Molyneaux, P. L., Maher, T. M., Noth, I., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103439 · Cited by 36

Authors: Atyeo, C., Fischinger, S., Zohar, T., Slein, M. D., Burke, J., Loos, C., McCulloch, D. J., Newman, K. L., Wolf, C., Yu, J., Shuey, K., Feldman, J., Hauser, B. M., Caradonna, T., Schmidt, A. G., Suscovich, T. J., Linde, C., Cai, Y., Barouch, D., Ryan, E. T., Charles, R. C., Lauffenburger, D., Chu, H., & Alter, G.
Affiliations: Harvard University (US)
Ragon Institute of MGH, MIT and Harvard (US)
University of Washington (US)
Beth Israel Deaconess Medical Center (US)
Boston Children's Hospital (US)
Massachusetts General Hospital (US)
Massachusetts Institute of Technology (US)
Corresponding author: Chu, Helen
Alter, Galit
ORCID: Atyeo, Caroline
Fischinger, Stephanie
Zohar, Tomer
Slein, Matthew D.
Burke, John
Loos, Carolin
McCulloch, Denise J.
Newman, Kira L.
Wolf, Caitlin
Yu, Jingyou
Shuey, Kiel
Feldman, Jared
Hauser, Blake Marie
Caradonna, Tim
Schmidt, Aaron G.
Suscovich, Todd J.
Linde, Caitlyn
Cai, Yongfei
Barouch, Dan
Ryan, Edward T.
Charles, Richelle C.
Lauffenburger, Douglas
Chu, Helen
Alter, Galit
Venue: Immunity
Publisher: Elsevier BV
Published: 2020-09
Volume: 53
Issue: 3
Pages: 524-532.e4
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2020.07.020
PMC: PMC7392190
OpenAlex: W3045933491
Cited by: 349
References: 52
Citations by year: 2026: 7 · 2025: 20 · 2024: 30 · 2023: 41 · 2022: 69 · 2021: 138 · 2020: 44
FWCI: 9.58
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Immunity (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: National Institute of Allergy and Infectious Diseases
Centers for Disease Control and Prevention
Bill and Melinda Gates Foundation
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, humoral immunity, spike-specific antibodies, nucleocapsid antibodies, disease outcome prediction, convalescence, hospitalized patients, immunodominant epitopes
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, Humans, Immunoglobulin G, Male, Middle Aged, Phosphoproteins, Pneumonia, Viral, Coronavirus Infections, Nucleocapsid Proteins, Immunity, Humoral, Pandemics, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks